Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 34.50 65,362 01:00:00
Bid Price Offer Price High Price Low Price Open Price
33.00 36.00 34.50 34.50 34.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.07 -16.91 -26.80 29
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:34 O 24,931 33.25 GBX

Diurnal (DNL) Latest News

More Diurnal News
Diurnal Takeover Rumours

Diurnal (DNL) Share Charts

1 Year Diurnal Chart

1 Year Diurnal Chart

1 Month Diurnal Chart

1 Month Diurnal Chart

Intraday Diurnal Chart

Intraday Diurnal Chart

Diurnal (DNL) Discussions and Chat

Diurnal Forums and Chat

Date Time Title Posts
15/10/201920:48Diurnal (MC Ј25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP132
29/7/201910:46Diurnal Group plc201

Add a New Thread

Diurnal (DNL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-17 16:21:0233.2524,9318,289.56O
2019-10-17 16:06:3434.5024,9318,601.20O
2019-10-17 10:21:1033.501,802603.67O
2019-10-17 10:21:0633.501,802603.67O
2019-10-17 10:08:5033.2512,5004,156.25O
View all Diurnal trades in real-time

Diurnal (DNL) Top Chat Posts

DateSubject
17/10/2019
09:20
Diurnal Daily Update: Diurnal Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DNL. The last closing price for Diurnal was 34.50p.
Diurnal Group Plc has a 4 week average price of 24.50p and a 12 week average price of 24.50p.
The 1 year high share price is 78p while the 1 year low share price is currently 21.50p.
There are currently 84,639,001 shares in issue and the average daily traded volume is 190,577 shares. The market capitalisation of Diurnal Group Plc is £29,200,455.35.
05/8/2019
10:53
bioking: Send an email to the company askting if they are still on track for NDA and MAA submission of their drugs and about potential partnerships . Below is the response Dear Mr XXXXXXXX, I can answer your questions as far as the information is already in the public domain. I can confirm the Alkindi NDA submission and Chronocort MAA submission remain on track for Q4 2019. We have disclosed to the market that we are in US licensing discussions. We have not put a timeline on a deal, other than to comment that we would like to have a commercial partner in place for Alkindi around the time of the NDA submission – so it is possible we could see partnerships before the end of 2019. We share your frustrations regarding the share price but do expect it to remain volatile until we get closer to potential approvals in the US and Europe. As I mentioned before, we have a very active investor relations programme, and do announce all significant newsflow as it happens. Best regards Richard Bungay
24/7/2019
15:24
frrinvest: TO BE PRECISE, BROKER PRICE TARGET £2.25 NOW! https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf from above link ... Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share. Conclusion Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for regulatory submission later this year. The share price also reflects the fact that the company will require more capitalin 2019 in the absence of any significant licensing deals. DNL’s US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator.
23/7/2019
19:47
74tom: The volume change caught my attention here, 5 consecutive days with volume over 500k shares with no RNS is impressive for DNL. An almost direct comparative is Shield Therapeutics; it fell from 200p to 17p in 2018 off the back of a misunderstood trial, since then it’s recovered back to £1.10. It’s clear that some serious investors see real value here, and gives me a lot of confidence that the share price can recover back towards £1 by the end of this year. Of course if we get news of a US partner then it’ll go significantly beyond that you would think!
22/7/2019
10:20
frrinvest: https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf from above link ... Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share. Conclusion Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for regulatory submission later this year. The share price also reflects the fact that the company will require more capitalin 2019 in the absence of any significant licensing deals. DNL’s US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator.
25/4/2019
08:52
costax1654x: From LSE: 225p Valuation!I must say this report sums up the situation very well, massive upside from here - 765% to be precise (225p target vs 26p current). https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf"Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL's first two products alone equates to £248m. Risk- adjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.""Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for a regulatory submission later this year. The share price also reflects the fact that the company will require more capital in 2019 in the absence of any significant licensing deals. DNL's US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator."
Diurnal share price data is direct from the London Stock Exchange
Your Recent History
LSE
DNL
Diurnal
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 00:00:15